Axsome Therapeutics (NASDAQ:AXSM) COO Mark Jacobson Sells 233 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 233 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the sale, the chief operating officer directly owned 4,517 shares of the company’s stock, valued at $1,030,689.06. The trade was a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Axsome Therapeutics Stock Performance

Shares of AXSM stock traded down $0.64 during trading hours on Tuesday, reaching $223.06. 1,019,532 shares of the company’s stock were exchanged, compared to its average volume of 882,597. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $234.29. The stock has a market capitalization of $11.47 billion, a P/E ratio of -59.80 and a beta of 0.59. The business has a fifty day moving average price of $171.73 and a 200-day moving average price of $163.34. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 246.90% and a negative net margin of 26.59%.The business had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. The company’s revenue was up 57.4% compared to the same quarter last year. Analysts predict that Axsome Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at $31,000. Ameriflex Group Inc. acquired a new position in Axsome Therapeutics during the fourth quarter worth $37,000. Versant Capital Management Inc raised its stake in Axsome Therapeutics by 20,300.0% during the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after acquiring an additional 203 shares in the last quarter. GAMMA Investing LLC raised its stake in Axsome Therapeutics by 65.4% during the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after acquiring an additional 106 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Axsome Therapeutics by 602.6% during the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after acquiring an additional 235 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AXSM has been the subject of a number of research analyst reports. Jefferies Financial Group upped their price target on Axsome Therapeutics from $245.00 to $275.00 and gave the stock a “buy” rating in a report on Monday. Piper Sandler reiterated an “overweight” rating and set a $258.00 price target on shares of Axsome Therapeutics in a report on Monday. Robert W. Baird upped their price target on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a report on Tuesday. Royal Bank Of Canada upped their target price on Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, UBS Group upped their target price on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $251.89.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.